Air from beehives comforts patients in Turkey, World News
Ceylan says people come regularly in late spring to Karaburun, in Turkey's Aegean coastal province of Izmir, mainly to supplement conventional treatment with traditional "apitherapy", a term derived from the Greek for bees.
Guests tend to stay several days in cabins in lush greenery, inhaling air from beehives for up to three hours a day, which Ceylan says helps with issues from allergies to migraines.
The government does not officially recognise the therapy though it is practiced by many other beekeepers round Turkey as well as in other countries including Germany and Russia.
Ceylan, who comes from a family of beekeepers and studied agriculture, started his bee farm in Karaburun 30 years ago. He has lobbied for years for the sector to be accepted, conducting research and presenting findings to officials.
"We are not against what we call Western medicine. After all, it is also very important too," he said, adding that his method goes hand-in-hand with conventional treatment.
"I have been doing this for fifteen years, trying to bring this into medicine." Childhood nostalgia
Ulku Ozman, 69, decided to try the therapy method after a friend suggested it when several surgeries and frequent use of medicines weakened her immune system.
In her nearly week-long visit, Ozman and others enter a cabin where ventilators connected to beehives deliver air.
Each session lasts 45 minutes, with participants moving every 15 minutes to breathe from three different beehives, each with a different smell. Guests pay around 5,000 lira (S$164) per day for the treatment plus accommodation and food.
Seated across from the beehives with ventilators on their faces, the guests take deep breaths.
Senay Ilham, 68, has breast cancer that metastasised to her spine but is in remission after receiving conventional treatment.
"This smell seems familiar. It's like it is (coming) from my childhood," she said, recalling being stung by bees while playing outside as children with beekeepers working nearby.
"(The beehive air) always brings me a breeze from these things. It relaxes me both psychologically and physically."
[[nid:715418]]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
11 hours ago
- Business Times
China biotech's stunning advance is changing the world's drug pipeline
[HONG KONG] The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation. The number of novel drugs in China, for cancer, weight-loss and more, entering into development ballooned to over 1,250 last year, far surpassing the European Union and nearly catching up to the US's count of about 1,440, an exclusive Bloomberg News analysis showed. And the drug candidates from the land once notorious for cheap knock-offs and quality issues are increasingly clearing high bars to win recognition from both drug regulators and Western pharmaceutical giants. The findings, gleaned from an analysis of a database maintained by pharma intelligence solutions provider Norstella, show a fundamental shift in medical innovation's centre of gravity. With US President Donald Trump already threatening tariffs on the pharmaceutical sector, China's biotech advances, the scale of which is slowly coming into view, risk becoming another realm of superpower rivalry such as artificial intelligence and electric vehicles. 'The scale itself is not something we have seen before,' said Helen Chen, managing partner at LEK Consulting in Shanghai, who has advised healthcare companies on their China strategy since 2003. 'The products are here, they are attractive and they are fast.' This shift has occurred at an unprecedented pace. When China began to overhaul its drug regulatory system in 2015, the country had just 160 compounds to contribute to the global pipeline of innovative drugs, or less than 6 per cent of the total, behind Japan and the UK. The reforms helped streamline reviews, enforced data quality standards and improved transparency. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up The government's 'Made in China 2025' plan to elevate manufacturing in 10 priority sectors also helped spur a flurry of investments in biotechnology. Altogether, they unleashed a boom led by foreign-educated and -trained scientists and entrepreneurs. 'Not only is it now almost at parity with the US but it has that growth trajectory,' said Daniel Chancellor, vice-president of thought leadership at Norstella. 'It wouldn't be sensationalist to suggest that China will overtake the US in the next few years purely in terms of numbers of drugs that it's bringing through into its pipeline.' Bloomberg News' data analysis focuses on innovative drugs, excluding generic combinations, reformulations and biosimilars. Numbers aside, the more stunning leap is in the quality of Chinese biotech innovation. While there's constant debate in the pharmaceutical industry on whether Chinese firms are capable of producing not just effective but needle-shifting new therapies, there's growing recognition on multiple fronts. The world's strictest regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency, increasingly view Chinese drugs as generally promising enough to justify devoting extra resources to speed up their review, handing them coveted industry designations such as priority review, breakthrough therapy designation or fast track status. The country is now slightly ahead of the EU in earning such expedited reviews as of 2024, the data shows, a remarkable edge over a region that previously produced drugs such as Wegovy. One of the early exemplars of Chinese innovation is a cell therapy that has shown promise to potentially cure a deadly blood cancer. First developed in China by Legend Biotech, it is now marketed by Johnson & Johnson, having won a few expedited review designations along the way, and considered superior to a competing US-originated therapy. Still, the absolute number of China-originated drugs winning these designations trail their US counterparts by a large margin. Risk-aversion remains a factor holding back Chinese pharmaceutical innovation: So far, top companies tend to focus on making better versions of existing therapies or new iterations of older ideas, and few are pioneering novel treatment approaches that have never been tried before, an endeavour that comes with a high risk of failure and is still led by the US, Europe and, to a lesser extent, Japan. Nevertheless, the biggest Chinese breakthroughs are increasingly being snapped up by pharmaceutical giants for record sums, a sign that the perennial competition for the next blockbuster drug is also shifting East. A novel cancer drug from Akeso, which came out more effective than Merck's Keytruda in a Chinese study last year, has been likened to China biotech's DeepSeek moment, spawning a new wave of global interest. The promise of topping Keytruda, the world's top-selling drug, also swelled the valuation of Summit Therapeutics, which in 2022 paid US$500 million upfront for the development and marketing rights in the US and other regions. Other multinational players such as Merck, AstraZeneca and Roche Holding have also scooped up Chinese assets. In May, Pfizer set a new record as it announced a US$1.2 billion upfront deal with 3SBio for a cancer drug similar to Akeso's. These deals are increasing in both value and frequency, according to biopharma deal database DealForma, signalling confidence that China-originated drugs are competitive internationally and can bring in substantial revenue. The volume of potential candidates coming out of China means multinational companies, who have a constant need to add new products to the mix, can 'cast their net wider than ever before', Norstella's Chancellor said. A key advantage that has fuelled the rise of Chinese biotech firms is their ability to conduct research cheaper and faster at every step of the way, from lab experiments and animal testing to human trials. Creating a new drug from scratch is notoriously time-consuming and expensive, and China's massive patient pool and centralised hospital network have become a significant accelerator. An analysis of the time taken for drugs to conduct various testing stages shows that doctors in China can recruit for trials much faster, for early trials for cancer and obesity drugs, they can complete patient enrolment in half the time compared to the US. The difference in costs means Chinese companies can afford to run multiple trials simultaneously to find a winner, or quickly launch new projects once a scientific idea is validated by other groups. Since 2021, China has become the top location for clinical research, initiating the largest number of new trials globally, according to GlobalData. 'They can leapfrog competitors in other countries,' said Andy Liu, head of China at Novotech Health Holdings, which helps companies run clinical trials. To be sure, clinical data in China is just a start. US regulators have made it clear that China-only trial results, no matter how positive, are not sufficient to support drug approvals. Chinese biotechs with the ambition to sell their drugs overseas must prove that their treatment benefits can be replicated in non-Chinese patients, through complex and slower-moving global studies. It may still be a few years before a critical mass of drugs sourced from China wins US and EU approvals, the gold standard for high-quality treatments, and become widely used in the Western world, but many in the industry believe that's inevitable. China's innovators comprise both cutting-edge biotech startups founded by foreign-educated entrepreneurs and old-guard Chinese pharmaceutical companies such as Jiangsu Hengrui Pharmaceuticals, which used to be one of the country's biggest generic drugmakers. The company poured billions of US dollars into shifting to innovative research and development after Beijing's campaign to lower generic drug prices made that sector less profitable. It's now the world's top-ranked pharmaceutical company for the number of new innovative drugs added to the research pipeline in the period of 2020 to 2024. Of the 50 companies that generated the highest number of innovative drug candidates between 2020 and 2024, 20 of them were Chinese, compared to five in the five years before. 'As we move forward, the fact that there's high-quality innovation in China in terms of biotech will no longer be a novelty,' said Ali Pashazadeh, founder and managing director of healthcare advisory firm Treehill Partners in London. 'It will just be an accepted part of the norm.' At a time when China and the US are engaged in renewed geopolitical spats, the growth of China's biotech ecosystem is causing alarm among some American politicians and business leaders. A congressional commission warned that the US risks losing its leadership position in yet another industry critical to national security. 'Biotech is one of the forefronts of the US-China tech rivalry,' said Jack Burnham, research analyst at the think tank Foundation for Defense of Democracies. In addition to economic implications and possible military applications of biotech, China's leverage on innovative therapies may be weaponised in a future conflict, he said, if Americans become dependent on those medicines. The perception of threat has spurred calls for the US government to stymie China's biotech growth, through restrictions such as export controls on scientific equipment and barriers to investment, and boost the domestic biotech sector, including by changing the regulatory environment to emulate countries where clinical trials are run more quickly. Robert F Kennedy, the US Secretary of Health and Human Services, recently pledged to 'Make American Biotech Accelerate'. Despite the risks of the newly combative relationship between the world's two biggest economies, Chinese drugmakers such as Akeso have set their sights on bringing their therapies to developed Western markets. 'The pharma industry is the best industry in the world,' Akeso chief executive officer Michelle Xia said. 'At the end of the day, what we do benefits patients in China, in the US and all around the world.' BLOOMBERG
Straits Times
2 days ago
- Straits Times
Serving up more delectable hospital food for patients
Sign up now: Get ST's newsletters delivered to your inbox Chef Kenneth Francisco, the hospital's assistant director of Group Hospitality and head of food services, serving the Chinese menu to Mr Leong Zheng Hao. SINGAPORE – When Mr Leong Zheng Hao was hospitalised at Alexandra Hospital with an infected ankle in June, he did not expect to be won over by the food. 'All the dishes in the Chinese menu looked very appetising and visually enticing, especially the colourful steamed vegetable rice. After tasting, I found all the dishes tasty and complemented each other,' he said. The 30-year-old, who is a chef himself, added: 'The sea bass with ginger and mandarin was very tender and fresh, and the dessert of steamed pear with rock sugar and goji berries tasted light with just the right amount of mild sweetness – a great way to end the meal.' The menu is the creation of award-winning chef Emmanuel Stroobant of Saint Pierre restaurant, who has been working on it with the public hospital's culinary team of about 20 people. It focuses on quality ingredients and refined cooking methods, but also adheres to the hospital's nutritional guidelines. For example, many dishes are steamed or boiled, and use less salt. After testing the menu on a few patients, including Mr Leong, the 'Featured Chef Menu' was launched at all of the hospital's wards on July 1. As more time and effort is needed to prepare these meals, the menu is available only once a week for patients on regular texture diets, at no extra cost. It is one of several menus that hospital patients can choose from. Top stories Swipe. Select. Stay informed. World US slaps 30% tariffs on EU and Mexico; EU warns of countermeasures Singapore S'pore shows what's possible when digital innovation is matched with purpose: UK foreign secretary Singapore Casual racism should be tackled by getting more people to understand it is not acceptable: David Neo Asia Fuel was cut off during take-off: Preliminary report on Air India crash Singapore Pulling back the curtain: A backstage look at the 2025 NDP show segment Singapore $3 cashback for hawker centre meals and shopping at heartland stores with DBS PayLah initiative Singapore Body of 62-year-old man recovered from waters off East Coast Park Asia Aerobridge hits Qantas plane at Sydney Airport, damaging engine, delaying flight Chef Emmanuel Stroobant of Saint Pierre restaurant with Alexandra Hospital's culinary team. PHOTO: ALEXANDRA HOSPITAL The 12-month collaboration, spearheaded by the hospital's food services team, will see quarterly refreshes using seasonal produce. It will also rotate between Asian, Chinese and Western cuisines. Mr Stroobant, 57, said he hopes to push back against the perception that hospital food is bland. 'I am always passionate about clean ingredients and mindful cooking,' he said. 'Hospital food is often associated with blandness or lack of variety, but I believe with a little creativity and attention to detail, it can be transformed into a delicious, healthy experience that complements the healing process.' More than half of the patients in the hospital's wards are aged 65 and above. Curating menus for them is his way of using what he has learnt to serve others, he said. 'My family and I have chosen to make Singapore our home, and we're grateful for the warmth and opportunities this country has given us,' said the Belgium-born chef, who moved to Singapore in 1999. 'Being part of this community also means giving back, and for me, the most meaningful way to do that is through food.' He has also made a foray into some schools to deliver nutritious meals. The collaboration also helps the hospital's culinary team to master healthy and flavourful techniques such as 'flavour layering' for patients with high blood pressure by using roasted vegetable stocks instead of salt. Another technique they learnt was 'heated marination', where meat like fish or chicken is first lightly cooked with fresh tomatoes, olives and garlic in olive oil. When the flavours are released, the meat is vacuum-packed while still hot, then baked to release their natural juices. This ensures that flavours are infused into the meat, with no heavy sauces needed. Chef Kenneth Francisco, the hospital's assistant director of g roup hospitality and head of food services, said it is not about 'fancy food'. 'It's about returning the choice to patients and they shouldn't have to choose between health and enjoyment,' he said. 'I hope this partnership will ignite my team's passion for redefining hospital meals, and continue to inspire us to do our part in improving patient care through delectable dining experiences.' The hospital's senior dietitian Lye Wye Li said: 'The recipes contain a good combination of ingredients to complement each other and draw out flavours without the use of extra seasoning, which helps in meeting therapeutic diet requirements.' The Singapore General Hospital (SGH) is also serving up delicious recipes with the help of two big industry names – Jumbo Group of Restaurants and 328 Katong Laksa. Its partnership with Jumbo started in 2023, with the restaurant chain sharing detailed recipes and preparation methods, followed by hands-on training sessions conducted by its chefs. Three dishes were launched in October 2023, and patient surveys showed an acceptance rate of 89 per cent. To date, thousands of patients have tried the steamed fish with Jumbo Seafood Nonya sauce, steamed fish with Jumbo Seafood chilli crab sauce, and Chao Ting Teochew pao fan. Steamed Fish with Jumbo Seafood chilli crab sauce served at the Singapore General Hospital. PHOTO: SINGAPORE GENERAL HOSPITAL Ms Eileen Lim, senior manager of SGH's Department of Food Services, said: 'Through these collaborations, we aim to elevate the variety and quality of food that we serve to our patients, making their healthy meals enjoyable. Most importantly, patients receive the nourishment they need for a complete and timely recovery.' She added that SGH is now in talks with Jumbo to renew its partnership after two years. Encouraged by the positive response to its first tie-up, the public hospital went on to partner 328 Katong Laksa in January 2025. For this meal, SGH increased the serving portion of bean sprouts and replaced cockles with prawns to meet nutritional needs and the Health Promotion Board's healthy eating guidelines. PHOTO: SINGAPORE GENERAL HOSPITAL To date, more than 5,000 patients have tried the dish created with 328 Katong Laksa at SGH. A survey found that 90 per cent of patients gave the new menu a favourable rating. SGH plans to work with other food and beverage brands that can offer a halal menu for Muslim patients. Besides enhancing the patients' dining experiences, such collaborations are welcomed by the staff too, Ms Lim said. She added: 'Our food service staff will also gain valuable professional development through expert training, elevating their culinary skills and job satisfaction.'
Straits Times
5 days ago
- Straits Times
Forum: Besides TCM, study other traditional methods for healthcare
Sign up now: Get ST's newsletters delivered to your inbox Patients often tell me they get relief, from minor indispositions to medical problems, using traditional methods after they tried the normal Western medical methodology which seemed to have failed them. The Ministry of Health already has a framework of standards for using traditional Chinese medicine (TCM) as part of public healthcare. While it is actively researching the efficacy of other TCM methods in treating afflictions, we should also study traditional modes of therapy adopted by other countries. India is a good example. The practice of Ayurvedic therapy, involving a holistic process of herbal medicine, dietary rebalancing, yoga, massage and purification programmes, has long kept India, with its population beyond a billion people, hale, hearty and fecund. Shouldn't we study and research these in detail too and then add them to our models of treatment? In our multiracial society, we should be able to accept and incorporate more than one set of traditional medical methodologies into the national healthcare system. Dr Yik Keng Yeong
